SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML

SuperGen, Inc. (NASDAQ:SUPG) today announced that it has enrolled the first patient in its first in human study of SGI-110, a second-generation hypomethylating agent, in patients with intermediate-2 or high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).

“We are pleased with the advancement of SGI-110 into the clinical stage. Moreover, we are honored to work with a group of highly distinguished collaborators, including members of the Stand Up to Cancer Epigenetics Dream Team, in the development of this important new agent”

SGI-110 was discovered and developed internally at SuperGen. The phase I study will be conducted in two stages. In the initial stage, patients will receive escalating doses of SGI-110 until the maximum tolerated dose (MTD) or the biologically effective dose (BED) is determined. Patients will be randomized to receive one of two dosing schedules of either a daily subcutaneous injection for 5 days, or a single weekly subcutaneous injection for 3 injections, both in a 28 day cycle. The second stage will include expansion of the number of patients treated at the selected dosing schedule to better evaluate both efficacy and safety in MDS and AML patients.

"We are pleased with the advancement of SGI-110 into the clinical stage. Moreover, we are honored to work with a group of highly distinguished collaborators, including members of the Stand Up to Cancer Epigenetics Dream Team, in the development of this important new agent," said Mohammad Azab, M.D., Chief Medical Officer.

A summary of preclinical efficacy, safety, and pharmacokinetics data of SGI-110 was presented at the recent American Society of Hematology conference. A downloadable copy of the poster can be found in the Pipeline section of the Company's website, http://www.supergen.com.

SOURCE SuperGen, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Lung cancer screening yields early diagnoses and increased cure rates in veterans